2017年乳腺癌新辅助治疗进展

doi:10.6040/j.issn.1671-7554.0.2017.896

摘要/Abstract

摘要： 乳腺癌的新辅助治疗包括在手术之前进行的化疗、内分泌治疗、靶向治疗等。肿瘤组织对于新辅助治疗的反应与疗效密切相关,甚至可能关系到患者治疗后的生存,特别是病理完全缓解(pCR)已经被提出作为临床效益预测的替代终点,新辅助治疗提供的这些信息为下一步治疗方案的制定指明了方向。近年来,对于新辅助治疗的研究不断深入,一些重要临床研究的结果也在不断更新并被重新解读,使我们的理念也在随之改变。在本文中我们简述了2017年有关新辅助治疗方面的新进展。

关键词: 乳腺癌, 新辅助治疗, 进展, 化疗, 内分泌治疗, 靶向治疗

Abstract: Neoadjuvant therapy is critical for treatment in patients with breast cancer, including chemotherapy, endocrine therapy, targeted therapy and so on. The response of tumor tissue, especially pathological complete response(PCR)has been proposed as a surrogate endpoint for prediction of long-term clinical benefit.The neoadjuvant therapy also provides information of tumor response and improves further therapeutic strategies. Recently, substantial developments have been made in neoadjuvant therapy with important clinical trials, and our concept of neoadjuvant therapy is also changing. This review showed the current perspectives in neoadjuvant therapy in 2017.

Key words: Breast cancer, Neoadjuvant therapy, Advance, Chemotherapy, Endocrine therapy, Targeted therapy

中图分类号:

R737.9

陈波,张磊. 2017年乳腺癌新辅助治疗进展[J]. 山东大学学报 (医学版), 2018, 56(1): 12-16.

CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16.

参考文献

[1] Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database[J]. J Am Coil Surg, 2015, 220(6): 1063-1069.
[2] King TA, Mowow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy[J]. Nat Rev Clin Oncol, 2015, 12(6): 335-343.
[3] Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer[J]. N Engl J Med, 2012, 366(26): 2438-2441.
[4] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(15): 1796-1804.
[5] Cortazar P, Zhang L, Untch M, et a1. Pathological complete response and long-term clinical benefit in breast cancer: the CT-NeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[6] Untch M, Konecny GE, Paepke S, et al. Current and future role of neoadjuvant therapy for breast cancer[J]. Breast, 2014, 23(5): 526-537.
[7] Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant therapy as a platform for drug development: current controversies and regulatory respectives[J]. Oncology(Williston Park), 2015, 29(11): 843-844.
[8] DeMichele A, Yee D, Berry DA, et al. The neoadjuvant model is still the future for drug development in breast cancer[J]. Clin Cancer Res, 2015, 21(13): 2911-2915.
[9] Sibylle L, Guatavo W, Valentina N, et al. Impact in delay of start of chemotherapy and surgery on PCR and survival in Breast cancer-a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials[C]. 2017 ASCO,Abstract 571. https://www.asco.org/
[10] Anna W, Sami B, Kenneth H, et al. Effect of neoadjuvant chemotherapy regimen choice in breast cancer patients with pathologic complete response[C]. 2017 ASCO, Abstract 570. https://www.asco.org/
[11] Silverd P, Richardsona L, Eklunda C, et al. Efficacy of neoadjuvant eisplatin in triple-negative breast cancer[J]. J Clin Oncol, 2010, 28(7): 1145-1153.
[12] Oakman C, Viale G, DiLeo A. Management of triple negative breast cancer[J]. Breast, 2010, 19(5): 312-321.
[13] Dent R, Trudeau M, Pritehard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt1): 4429-4434.
[14] Von MG, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatinin patients with triple-negative and Her-2-positive early breast cancer(GeparSixto; GBG 66): a randomised phase 2 trial[2]. Lancet Oncol, 2014, 15(7): 747-756.
[15] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and /or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[16] Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016, 375(1): 23-34.
[17] Daniel E, Nathaly PN, Hugo AF, et al. Improving pathological responses in locally advanced triple negative breast cancer comparison between CbD and AT-T regimens[C]. 2017 ASCO,Abstract 585. https://www.asco.org/
[18] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 76(22): 2147-2159. doi: 10.1056/NEJMoa1612645.
[19] von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2013, 31(29): 3623-3630. doi: 10.1200/JCO.2012.45.0940.
[20] Hee JK, Woo CN, Eun Sook L, et al. A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer(KBCSG 012)[C]. 2017 ASCO, NEST Trial. https://www.asco.org/
[21] Gianni L, Pienkowski T, Im YH, et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-pOSitive breast cancer(Neosphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[22] Jens H, Eileen H, JOSe B, et al. Survival outcomes of the neoaltto study: updated results of a randomized multicenter phase 3 neoadjuvant trial[C]. 2017 ASCO,Abstract 512. https://www.asco.org/
[23] van Ramshorst MS, van Werkhoven E, Mandjes IA, et al. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-pOSitive breast cancer: the TRAIN-2 study(BOOG 2012-03)[C]. 2017 ASCO,Abstract 507. https://www.asco.org/
[24] Justin S, Yauheni VB, Valery B, et al. Double-blind, randomized phase 3 study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate, versus reference trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer[C]. 2017 ASCO,Abstract 510. https://www.asco.org/
[25] Rita N, Minetta C, Liu, et al. Pembrolizum ab plus standard neoadjuvant therapy for high-risk breast cancer: Result from the I-SPY 2 Trial[C]. 2017 ASCO,I-SPY 2 Trial. https://www.asco.org/

相关文章 15

[1]	阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[2]	林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46.
[3]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[4]	杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5.
[5]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[6]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[7]	赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29.
[8]	王沂峰,何丽清. 外阴癌腹股沟淋巴结手术的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 103-109,116.
[9]	史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[10]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[11]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[12]	孙庆杰,张怡莎,管尚慧,凤志慧. 丙戊酸对134例放疗神经胶质瘤患者预后生存和肿瘤复发的影响[J]. 山东大学学报 (医学版), 2021, 59(8): 80-85.
[13]	王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.
[14]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[15]	孔雪,李娟,段伟丽,史爽,李培龙,杜鲁涛,毛海婷,王传新. 长链非编码RNA AC012073.1对乳腺癌细胞迁移侵袭的影响及临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 70-78.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed